Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up

- Mathers, John C., Elliott, Faye, Lindblom, Annika, Morrison, Patrick J., Rashbass, Jem, Ramesar, Raj S., Seppälä, Toni T., Thomas, Huw J. W., Sheth, Harsh J., Pylvänäinen, Kirsi, Reed, Lynn, Borthwick, Gillian M., Macrae, Finlay, Bishop, D. Timothy, Burn, J, Boussioutas, A, Brewer, C, Cook, J, Eccles, D, Ellis, A, Hodgson, SV, Lubinski, J, Maher, ER, Mecklin, Jukka-Pekka, Porteous, MEM, Sampson, J, Scott, Rodney J., Side, L, Bisgaard, ML, Chu, C, Fidalgo, P, Gallinger, S, Homfray, T, Möslein, Gabriela, Hutter, P, Leite, J, MacKay, J, Marks, CG, Miles, A, Murday, V, Oliani, C, Olschwang, S, Segura, PP, Pichert, G, McRonald, Fiona E., Sappino, AP, Tempesta, A, Vasen, HFA, Walpole, I, Langman, C, Shand, B, Bacon, A, Bertario, Lucio, Evans, D. Gareth, Gerdes, Anne-Marie, Ho, Judy W. C.

Cancer Risks for PMS2-Associated Lynch Syndrome.

- Ten Broeke, Sanne W., van der Klift, Heleen M., Gallinger, Steven, Gomez Garcia, Encarna, Figueiredo, Jane C., Haile, Robert, Hampel, Heather L., Hopper, John L., Hoogerbrugge, Nicoline, von Knebel Doeberitz, Magnus, Le Marchand, Loic, Letteboer, Tom G. W., Tops, Carli M. J., Jenkins, MA, Lindblom, A, Lindor, NM, Mensenkamp, AR, Møller, P, Newcomb, PA, van Os, TAM, Pearlman, R, Pineda, M, Rahner, N, Aretz, Stefan, Redeker, EJW, Olderode-Berends, MJW, Rosty, C, Schackert, HK, Scott, Rodney, Senter, L, Spruijt, L, Steinke-Lange, V, Suerink, M, Thibodeau, S, Bernstein, Inge, Vos, YJ, Wagner, A, Winship, I, Hes, FJ, Vasen, HFA, Wijnen, JT, Nielsen, M, Win, AK, Buchanan, Daniel D., de la Chapelle, Albert, Capella, Gabriel, Clendenning, Mark, Engel, Christoph